NO975581L - Fremgangsmåte for å redusere bentap - Google Patents
Fremgangsmåte for å redusere bentapInfo
- Publication number
- NO975581L NO975581L NO975581A NO975581A NO975581L NO 975581 L NO975581 L NO 975581L NO 975581 A NO975581 A NO 975581A NO 975581 A NO975581 A NO 975581A NO 975581 L NO975581 L NO 975581L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- bone loss
- pyrrolidinyl
- alkyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glass Compositions (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
Abstract
Foreliggende oppfinnelse skaffer tilveie en fremgangsmåte for å redusere bentapeffekt av en forbindelse med formel II eller et farmasøytisk akseptabelt salt derav, der nevnte formel II blir administrert til et pattedyr som har behov for behandling, og omfatter samtidig eller sekvensiell administrering til nevnte pattedyr av en effektiv mengde av en forbindelse med formel I, der hver R1 er uavhengig av hverandre -H, -OH, -0(CCalkyl), -OCOCH, -OCO(C,-Calkyl) eller -OS0(C-Calkyl); og R2 er 1-piperidinyl, 1-pyrrolidinyl, metyl-1-pyrrolidinyI, dimetyl-l-pyrrolidinyl, 4-morfolino, dimetylamino, dietylamino eller 1-heksametylenimino, eller et farmasøytisk akseptabelt salt derav. Det blir også beskrevet en fremgangsmåte for å begrense bentap indusert ved administrering av en formel II forbindelse og omfatter samtidig eller sekvensiell administrering av et benanabolsk middel. Det blir også beskrevet farmasøytiske sammensetninger.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/467,475 US5599822A (en) | 1995-06-06 | 1995-06-06 | Methods for minimizing bone loss |
PCT/US1996/008875 WO1996039138A1 (en) | 1995-06-06 | 1996-06-05 | Methods for minimizing bone loss |
Publications (2)
Publication Number | Publication Date |
---|---|
NO975581D0 NO975581D0 (no) | 1997-12-03 |
NO975581L true NO975581L (no) | 1997-12-03 |
Family
ID=23855853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO975581A NO975581L (no) | 1995-06-06 | 1997-12-03 | Fremgangsmåte for å redusere bentap |
Country Status (22)
Country | Link |
---|---|
US (1) | US5599822A (no) |
EP (1) | EP0747054B1 (no) |
JP (1) | JPH11507051A (no) |
KR (1) | KR19990022498A (no) |
CN (1) | CN1192145A (no) |
AU (1) | AU696209B2 (no) |
BR (1) | BR9608389A (no) |
CA (1) | CA2223055A1 (no) |
CO (1) | CO4700446A1 (no) |
CZ (1) | CZ382997A3 (no) |
DE (1) | DE69623074T2 (no) |
EA (1) | EA000763B1 (no) |
ES (1) | ES2181849T3 (no) |
HU (1) | HUP9900849A3 (no) |
IL (1) | IL118590A (no) |
NO (1) | NO975581L (no) |
PL (1) | PL323935A1 (no) |
TR (1) | TR199701507T1 (no) |
TW (1) | TW372969B (no) |
WO (1) | WO1996039138A1 (no) |
YU (1) | YU34396A (no) |
ZA (1) | ZA964778B (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
DE19825591A1 (de) * | 1998-06-09 | 1999-12-23 | Jenapharm Gmbh | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
WO2001035946A2 (en) * | 1999-11-15 | 2001-05-25 | New Millennium Pharmaceutical Research, Inc. | Intranasal administration of raloxifene and tamoxifen |
EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
US20050124537A1 (en) * | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
EP1180364A1 (en) * | 2000-08-15 | 2002-02-20 | Octagene GmbH | Steroid hormones as transfer agents |
CA2490580C (en) | 2002-07-22 | 2012-12-11 | Eli Lilly And Company | Selective estrogen receptor modulators containing a naphthalene group |
CA2567056A1 (en) | 2004-05-10 | 2005-12-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
ES2568259T3 (es) * | 2004-05-13 | 2016-04-28 | Alza Corporation | Aparato y método para la administración transdérmica de agentes de hormona paratiroidea |
WO2007044375A2 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
AU2006299887A1 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | PTH formulations and methods of use |
CN110809473A (zh) * | 2017-06-01 | 2020-02-18 | 延世大学校产学协力团 | 用于预防或治疗骨相关疾病的药物组合物 |
CN108785264A (zh) * | 2018-07-03 | 2018-11-13 | 威海贯标信息科技有限公司 | 一种达那唑片剂组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3135743A (en) * | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
-
1995
- 1995-06-06 US US08/467,475 patent/US5599822A/en not_active Expired - Fee Related
-
1996
- 1996-06-05 CO CO96029177A patent/CO4700446A1/es unknown
- 1996-06-05 PL PL96323935A patent/PL323935A1/xx unknown
- 1996-06-05 YU YU34396A patent/YU34396A/sh unknown
- 1996-06-05 AU AU60430/96A patent/AU696209B2/en not_active Ceased
- 1996-06-05 KR KR1019970708979A patent/KR19990022498A/ko not_active Application Discontinuation
- 1996-06-05 CN CN96195975A patent/CN1192145A/zh active Pending
- 1996-06-05 JP JP9501343A patent/JPH11507051A/ja active Pending
- 1996-06-05 WO PCT/US1996/008875 patent/WO1996039138A1/en not_active Application Discontinuation
- 1996-06-05 TR TR97/01507T patent/TR199701507T1/xx unknown
- 1996-06-05 BR BR9608389A patent/BR9608389A/pt unknown
- 1996-06-05 CA CA002223055A patent/CA2223055A1/en not_active Abandoned
- 1996-06-05 EA EA199800013A patent/EA000763B1/ru not_active IP Right Cessation
- 1996-06-05 CZ CZ973829A patent/CZ382997A3/cs unknown
- 1996-06-05 HU HU9900849A patent/HUP9900849A3/hu unknown
- 1996-06-06 ES ES96304180T patent/ES2181849T3/es not_active Expired - Lifetime
- 1996-06-06 EP EP96304180A patent/EP0747054B1/en not_active Expired - Lifetime
- 1996-06-06 IL IL11859096A patent/IL118590A/xx not_active IP Right Cessation
- 1996-06-06 DE DE69623074T patent/DE69623074T2/de not_active Expired - Fee Related
- 1996-06-06 ZA ZA9604778A patent/ZA964778B/xx unknown
- 1996-06-06 TW TW085106756A patent/TW372969B/zh active
-
1997
- 1997-12-03 NO NO975581A patent/NO975581L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA964778B (en) | 1997-12-08 |
CA2223055A1 (en) | 1996-12-12 |
YU34396A (sh) | 1999-07-28 |
EP0747054B1 (en) | 2002-08-21 |
AU696209B2 (en) | 1998-09-03 |
CN1192145A (zh) | 1998-09-02 |
US5599822A (en) | 1997-02-04 |
EP0747054A2 (en) | 1996-12-11 |
NO975581D0 (no) | 1997-12-03 |
EA199800013A1 (ru) | 1998-06-25 |
EP0747054A3 (en) | 1997-03-05 |
BR9608389A (pt) | 1999-05-04 |
WO1996039138A1 (en) | 1996-12-12 |
HUP9900849A3 (en) | 1999-11-29 |
TW372969B (en) | 1999-11-01 |
AU6043096A (en) | 1996-12-24 |
CO4700446A1 (es) | 1998-12-29 |
IL118590A0 (en) | 1996-10-16 |
EA000763B1 (ru) | 2000-04-24 |
DE69623074D1 (de) | 2002-09-26 |
DE69623074T2 (de) | 2003-05-08 |
ES2181849T3 (es) | 2003-03-01 |
JPH11507051A (ja) | 1999-06-22 |
KR19990022498A (ko) | 1999-03-25 |
PL323935A1 (en) | 1998-04-27 |
IL118590A (en) | 1999-10-28 |
CZ382997A3 (cs) | 1998-09-16 |
HUP9900849A2 (hu) | 1999-09-28 |
TR199701507T1 (xx) | 1998-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO975581L (no) | Fremgangsmåte for å redusere bentap | |
RU94045846A (ru) | Применение производных бензотиофена для ингибирования тромбина | |
NO950774L (no) | Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol | |
RU94043811A (ru) | Применение 2-фенил-3-ароилбензтиофенов для лечения менструальных симптомов, фармацевтические композиции | |
RU2004116472A (ru) | Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 | |
PT958296E (pt) | Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas | |
NO20063382L (no) | Nye kinolinderivater | |
KR960701033A (ko) | 효능있는 칼슘 길항 및 산화방지 활성을 모두 갖는 화합물, 및 세포보호제로서 그것의 사용방법(compounds having both potent calcium antagonist and antioxidant activity and use there of as cytoprotective agents) | |
ES2141957T3 (es) | Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales. | |
RU94044436A (ru) | Способы подавления атрофии кожи и влагалища | |
AR003930A1 (es) | Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados | |
RU94045149A (ru) | Средство ингибирования легочных гипертонических заболеваний | |
BR9807079A (pt) | Composto de derivado de 16-hidróxi-11- (fenil substituìdo) - estra-4,9-dieno, uso de um composto, formulação farmacêutica, e processo para a preparação de um composto. | |
ATE240948T1 (de) | Naphthyl- und dihydronaphthylverbindungen als arzneimittel | |
KR940703655A (ko) | 약제학적 조성물과 그 제조방법 | |
ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
DE69532079D1 (de) | Benzofuranverbindungen, präparate und verfahren | |
NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
MY106401A (en) | N-imidazolyl-and-n-imidazolymethyl-derivatives of substituted bicyclic compounds. | |
RU94045272A (ru) | Применение 2-фенил-3-ароилбензотиофенов для лечения овариального дисгенеза, задержки полового созревания или сексуального инфантелизма | |
DK0733035T3 (da) | Tricykliske derivater og farmaceutiske præparater, der indeholder dem | |
KR940009179A (ko) | 벤조푸란 유도체, 그의 제조 방법, 그를 함유한 제약조성물 및 그의 의약으로서의 용도 | |
NO975560L (no) | Fremgangsmåte for å redusere bentap | |
NO971229D0 (no) | Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger | |
DK0688218T3 (da) | Interleukin-1-inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |